Fig. 2.

Time-to-Recovery, Modified Intention-To-Treat Population. Aalen-Johansen cumulative incidence curves showing the proportion of recovered patients in the mITT population up to 60 days of follow-up post randomisation in the presence of death prior to recovery as a competing risk. Numbers below each panel show patients at risk across time. Shaded areas show 95% pointwise confidence intervals. A. Apremilast arm, B. Cenicriviroc arm, C. Icatibant arm, D. IC14 arm, E. Celecoxib/Famotidine arm, F. Dornase arm.